All In Biotech

Drug Trial Radar · NCT06775041

Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS)

A Phase 2a, Randomized, Open-Label Study to Determine the Optimal Dose and Evaluate the Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS)

Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Jan 13, 2025

Primary completion

Mar 30, 2026

Study completion Apr 30, 2026

Sponsor

Sponsor type
Industry
First posted
Jan 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers will compare treatment with progerinin plus lonafarnib vs lonafarnib alone to assess optimal dosing, safety, tolerability, and pharmacokinetics in patients with Hutchinson-Gilford Progeria Syndrome (HGPS). Subjects in the randomized study arms will continue to take the standard of care (SOC), lonafarnib, and will be randomized to either take SOC alone or in combination with progerinin.

Conditions

  • Hutchinson-Gilford Progeria Syndrome

Interventions

  • ProgerininDrug

    Dosing will be determined based on body weight. Dosing ranges from 500mg to 1500mg daily. Progerinin is available in sachets of 250 mg or 350 mg for oral use.

  • LonafarnibDrug

    Lonafarnib is considered as the standard of care (SOC). Subjects in the randomized arms will continue taking lonafarnib per the package insert. Subjects in the lonafarnib naïve arm will initiate lonafarnib as per FDA-approved study 07-01-7505.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in plasma progerin concentrationTime frame: Baseline and Month 4 of each cohort
  2. Incidence of Dose Limiting Toxicities (DLTs)Time frame: From baseline to follow-up (approximately 13 months)
  3. Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)Time frame: From baseline to follow-up (approximately 13 months)
  4. Incidence of withdrawals due to Adverse Events (AEs)Time frame: From baseline to follow-up (approximately 13 months)
  5. Incidence of Treatment-Related Adverse EventsTime frame: From baseline to follow-up (approximately 13 months)
  6. Incidence of Serious Adverse Events (SAEs)Time frame: From baseline to follow-up (approximately 13 months)
  7. Change/shifts in laboratory values from baselineTime frame: From baseline to follow-up (approximately 13 months)
  8. Change in blood pressure from baselineTime frame: From baseline to follow-up (approximately 13 months)
  9. Change in heart rate from baselineTime frame: From baseline to follow-up (approximately 13 months)
  10. Change in respiratory rate from baselineTime frame: From baseline to follow-up (approximately 13 months)
  11. Change in temperature from baselineTime frame: From baseline to follow-up (approximately 13 months)
  12. Change in Electrocardiogram (ECG) parameter, ventricular rate (beats per minute), from baselineTime frame: From baseline to follow-up (approximately 13 months)
  13. Change in Electrocardiogram (ECG) parameter, PR interval (msec), from baselineTime frame: From baseline to follow-up (approximately 13 months)
  14. Change in Electrocardiogram (ECG) parameter, QRS interval (msec), from baselineTime frame: From baseline to follow-up (approximately 13 months)
  15. Change in Electrocardiogram (ECG) parameter, QT interval (msec), from baselineTime frame: From baseline to follow-up (approximately 13 months)
  16. Change in Electrocardiogram (ECG) parameter, QTc interval (msec), from baselineTime frame: From baseline to follow-up (approximately 13 months)
  17. Maximum observed plasma drug concentration (Cmax)Time frame: Baseline, and pre-dose (0 hr) and 2-5 hr post-dose at Month 4 of each cohort
  18. Apparent terminal elimination half-life (t1/2)Time frame: Baseline, and pre-dose (0 hr) and 2-5 hr post-dose at Month 4 of cohort1 & cohort 2
  19. Time to maximum observed plasma drug concentration (Tmax)Time frame: Baseline, and pre-dose (0 hr) and 2-5 hr post-dose at Month 4 of cohort1 & cohort 2
  20. Area under the plasma drug concentration-time curve (AUC) from time 0 to the end of the dosing period (AUC0-τ)Time frame: Baseline, and pre-dose (0 hr) and 2-5 hr post-dose at Month 4 of cohort1 & cohort 2
  21. Clearance (CL)Time frame: Baseline, and pre-dose (0 hr) and 2-5 hr post-dose at Month 4 of cohort1 & cohort 2
  22. Covariates: AgeTime frame: Baseline, and pre-dose (0 hr) and 2-5 hr post-dose at Month 4 of each cohort
  23. Covariates: Body weightTime frame: Baseline, and pre-dose (0 hr) and 2-5 hr post-dose at Month 4 of each cohort

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Boston Children's Hospital

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.